Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
Tuan VuNatalie AnthonyRaul AlsinaBrittany HarveyAllison SchleutkerJerrica FariasSamuel DangNiraja SureshClifton GoochPublished in: Muscle & nerve (2021)
Transition to SCIg was associated with maintained efficacy and improved QOL.
Keyphrases